Drug Trial Radar · NCT07716865
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Apr 3, 2024
Primary completion
Dec 29, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Arctic TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA). In the study participants receive increasing dose or active treatment (250 mg vs 500mg vs 750 mg) or matched placebo in the form of tablets BID.
Conditions
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
- Hemorrhage Brain
- Hemorrhage Cerebral
Interventions
NACADrug
250 mg tablets BID, increasing dosage from 250 mg BID to 750 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Through study completion, up to 24 months
- Frequency of cerebral bleeding eventsTime frame: Through study completion, up to 24 months
- Safety labs results within normal rangeTime frame: Through study completion, up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Landspitali University Hospital
Reykjavik, Iceland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.